WASHINGTON – The Supreme Court has sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.
Continue Reading Below
The justices ruled Tuesday that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone. The decision allows the Israel-based company to keep its exclusive rights to the drug until September 2015.
Copaxone generates about $4 billion in annual sales for Teva.
Teva had argued that the U.S. Court of Appeals for the Federal Circuit should not have second-guessed factual findings made by a federal district court that had earlier ruled in Teva's favor.
The justices agreed that the Federal Circuit should have deferred to factual findings made by the lower court.